The FOXM1-induced resistance to oxaliplatin is partially mediated by its novel target gene Mcl-1 in gastric cancer cells

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1849, Issue 3, 2015, Pages 290-299

  Hu, Chang Jiang ^a   Wang, Bin ^a   Tang, Bo ^a   Chen, Bai jun ^a   Xiao, Yu Feng ^a   Qin, Yong ^a   Yong, Xin ^a   Luo, Gang ^a   Zhang, Jian Wei ^a   Zhang, Dan ^a   Li, Song ^b   He, Fengtian ^a   Yang, Shi Ming ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Apoptosis; FOXM1; Mcl 1; Oxaliplatin

Indexed keywords

FORKHEAD BOX M1 PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; MESSENGER RNA; OXALIPLATIN; PROTEIN MCL 1; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTORS; FOXM1 PROTEIN, HUMAN; MCL1 PROTEIN, HUMAN; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; ORGANOPLATINUM COMPOUNDS;

ADULT; ADVANCED CANCER; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GASTRIC CANCER CELL LINE; GEL MOBILITY SHIFT ASSAY; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; RECEIVER OPERATING CHARACTERISTIC; STOMACH CANCER; TUMOR DIFFERENTIATION; TUMOR VOLUME; UPREGULATION; AGED; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETICS; HUMANS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROMOTER REGIONS, GENETIC; STOMACH NEOPLASMS;

AGED; APOPTOSIS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROMOTER REGIONS, GENETIC; STOMACH NEOPLASMS;

EID: 84921467017     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2014.11.008     Document Type: Article

References (46)

1. Kang C., Song J.J., Lee J., Kim M.Y. Epigenetics: an emerging player in gastric cancer. World J. Gastroenterol. 2014, 20:6433-6447.
2. Montagnani F., Turrisi G., Marinozzi C., Aliberti C., Fiorentini G. Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer 2011, 14:50-55.
3. Wong R., Cunningham D. Optimising treatment regimens for the management of advanced gastric cancer. Ann. Oncol. 2009, 20:605-608.
4. Yang M., Shan X., Zhou X., Qiu T., Zhu W., Ding Y., Shu Y., Liu P. miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. Anti Cancer Agents Med. Chem. 2014, 14:884-891.
5. Zhou X., Su J., Zhu L., Zhang G. Helicobacter pylori modulates cisplatin sensitivity in gastric cancer by down-regulating miR-141 expression. Helicobacter 2014, 19:174-181.
6. Fu X., Feng J., Zeng D., Ding Y., Yu C., Yang B. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/Erk-dependent pathways. Biosci. Rep. 2014, 34(2):art:e00094.
7. Park J., Ko Y.S., Yoon J., Kim M.A., Park J.W., Kim W.H., Choi Y., Kim J.H., Cheon Y., Lee B.L. The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway. Gastric Cancer 2014, 17:423-430.
8. Huang S., Chen M., Shen Y., Shen W., Guo H., Gao Q., Zou X. Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett. 2012, 315:198-205.
9. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell. Mol. Life Sci. 2009, 68:1326-1336.
10. Akagi H., Higuchi H., Sumimoto H., Igarashi T., Kabashima A., Mizuguchi H., Izumiya M., Sakai G., Adachi M., Funakoshi S., Nakamura S., Hamamoto Y., Kanai T., Takaishi H., Kawakami Y., Hibi T. Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells. Gastric Cancer 2013, 16:100-110.
11. Likui W., Qun L., Wanqing Z., Haifeng S., Fangqiu L., Xiaojun L. Prognostic role of myeloid cell leukemia-1 protein (Mcl-1) expression in human gastric cancer. J. Surg. Oncol. 2009, 100:396-400.
12. Myatt S.S., Lam E.W. Targeting FOXM1. Nat. Rev. Cancer 2008, 8:242.
13. Halasi M., Pandit B., Wang M., Nogueira V., Hay N., Gartel A.L. Combination of oxidative stress and FOXM1 inhibitors induces apoptosis in cancer cells and inhibits xenograft tumor growth. Am. J. Pathol. 2013, 183:257-265.
14. Uddin S., Ahmed M., Hussain A., Abubaker J., Al-Sanea N., AbdulJabbar A., Ashari L.H., Alhomoud S., Al-Dayel F., Jehan Z., Bavi P., Siraj A.K., Al-Kuraya K.S. Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy. Am. J. Pathol. 2011, 178:537-547.
15. Qu K., Xu X., Liu C., Wu Q., Wei J., Meng F., Zhou L., Wang Z., Lei L., Liu P. Negative regulation of transcription factor FoxM1 by p53 enhances oxaliplatin-induced senescence in hepatocellular carcinoma. Cancer Lett. 2013, 331:105-114.
16. Okada K., Fujiwara Y., Takahashi T., Nakamura Y., Takiguchi S., Nakajima K., Miyata H., Yamasaki M., Kurokawa Y., Mori M., Doki Y. Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer. Ann. Surg. Oncol. 2013, 20:1035-1043.
17. Lin J., Zheng Y., Chen K., Huang Z., Wu X., Zhang N. Inhibition of FOXM1 by thiostrepton sensitizes medulloblastoma to the effects of chemotherapy. Oncol. Rep. 2013, 30:1739-1744.
18. Kwok J.M., Peck B., Monteiro L.J., Schwenen H.D., Millour J., Coombes R.C., Myatt S.S., Lam E.W. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol. Cancer Res. 2010, 8:24-34.
19. Zhou J., Wang Y., Yin X., He Y., Chen L., Wang W., Liu T., Di W. FOXM1 modulates cisplatin sensitivity by regulating EXO1 in ovarian cancer. PLoS ONE 2014, 9:e96989.
20. Ni Z., Wang B., Dai X., Ding W., Yang T., Li X., Lewin S., Xu L., Lian J., He F. HCC cells with high levels of Bcl-2 are resistant to ABT-737 via activation of the ROS-JNK-autophagy pathway. Free Radic. Biol. Med. 2014, 70:194-203.
21. Bhat U.G., Halasi M., Gartel A.L. Thiazole antibiotics target FoxM1 and induce apoptosis in human cancer cells. PLoS ONE 2009, 4:e5592.
22. Murphy A.C., Weyhenmeyer B., Noonan J., Kilbride S.M., Schimansky S., Loh K.P., Kogel D., Letai A.G., Prehn J.H., Murphy B.M. Modulation of Mcl-1 sensitizes glioblastoma to TRAIL-induced apoptosis. Apoptosis 2014, 19:629-642.
23. Pareja F., Macleod D., Shu C., Crary J.F., Canoll P.D., Ross A.H., Siegelin M.D. PI3K and Bcl-2 inhibition primes glioblastoma cells to apoptosis through downregulation of Mcl-1 and phospho-BAD. Mol. Cancer Res. 2014, 12:987-1001.
24. Xie G., Tang H., Wu S., Chen J., Liu J., Liao C. The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo. Int. J. Oncol. 2014, 45:804-812.
25. Li X., Yao R., Yue L., Qiu W., Qi W., Liu S., Yao Y., Liang J. FOXM1 mediates resistance to docetaxel in gastric cancer via up-regulating Stathmin. J. Cell. Mol. Med. 2014, 18:811-823.
26. Karami H., Baradaran B., Esfehani A., Sakhinia M., Sakhinia E. Down-regulation of Mcl-1 by small interference RNA induces apoptosis and sensitizes HL-60 leukemia cells to etoposide. Asian Pac. J. Cancer Prev. 2014, 15:629-635.
27. Michels J., Obrist F., Vitale I., Lissa D., Garcia P., Behnam-Motlagh P., Kohno K., Wu G.S., Brenner C., Castedo M., Kroemer G. MCL-1 dependency of cisplatin-resistant cancer cells. Biochem. Pharmacol. 2014, 92:55-61.
28. Huang T., Gong W.H., Li X.C., Zou C.P., Jiang G.J., Li X.H., Qian H. Oxaliplatin sensitizes OS cells to TRAIL-induced apoptosis via down-regulation of Mcl1. Asian Pac. J. Cancer Prev. 2012, 13:3477-3481.
29. Liu H.F., Hu H.C., Chao J.I. Oxaliplatin down-regulates survivin by p38 MAP kinase and proteasome in human colon cancer cells. Chem. Biol. Interact. 2010, 188:535-545.
30. Allen J.E., El-Deiry W.S. Oxaliplatin uses JNK to restore TRAIL sensitivity in cancer cells through Bcl-xL inactivation. Gastroenterology 2011, 141:430-434.
31. Zecevic A., Sampath D., Ewald B., Chen R., Wierda W., Plunkett W. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease. Clin. Cancer Res. 2011, 17:4731-4741.
32. Ngan C.Y., Yamamoto H., Takagi A., Fujie Y., Takemasa I., Ikeda M., Takahashi-Yanaga F., Sasaguri T., Sekimoto M., Matsuura N., Monden M. Oxaliplatin induces mitotic catastrophe and apoptosis in esophageal cancer cells. Cancer Sci. 2008, 99:129-139.
33. Seetharam R., Sood A., Goel S. Oxaliplatin: pre-clinical perspectives on the mechanisms of action, response and resistance. Ecancermedicalscience 2009, 3:153.
34. Li X., Qiu W., Liu B., Yao R., Liu S., Yao Y., Liang J. Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel. J. Transl. Med. 2013, 11:204.
35. Li X., Qi W., Yao R., Tang D., Liang J. Overexpressed transcription factor FOXM1 is a potential diagnostic and adverse prognostic factor in postoperational gastric cancer patients. Clin. Transl. Oncol. 2014, 16:307-314.
36. Koo C.Y., Muir K.W., Lam E.W. FOXM1: from cancer initiation to progression and treatment. Biochim. Biophys. Acta 2012, 1819:28-37.
37. Isomoto H., Kobayashi S., Werneburg N.W., Bronk S.F., Guicciardi M.E., Frank D.A., Gores G.J. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005, 42:1329-1338.
38. Wang JM C.J., Chen W., Kuo M.L., Yen J.J., Yang-Yen H.F. The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol. Cell. Biol. 1999, 19:6195-6206.
39. Hu J., Dang N., Menu E., De Bryune E., Xu D., Van Camp B., Van Valckenborgh E., Vanderkerken K. Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition. Blood 2012, 119:826-837.
40. Sheng Z., Li L., Zhu L.J., Smith T.W., Demers A., Ross A.H., Moser R.P., Green M.R. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat. Med. 2010, 16:671-677.
41. Piret J.P., Minet E., Cosse J.P., Ninane N., Debacq C., Raes M., Michiels C. Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J. Biol. Chem. 2005, 280:9336-9344.
42. Wang B., Ni Z., Dai X., Qin L., Li X., Xu L., Lian J., He F. The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells. Mol. Cancer 2014, 13:98.
43. Maurer U., Charvet C., Wagman A.S., Dejardin E., Green D.R. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol. Cell 2006, 21:749-760.
44. Domina AM V.J., Gregory M.A., Hann S.R., Craig R.W. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 2004, 23:5301-5315.
45. Xu N., Zhang X., Wang X., Ge H.Y., Wang X.Y., Garfield D., Yang P., Song Y.L., Bai C.X. FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells. Acta Pharmacol. Sin. 2012, 33:675-681.
46. Khongkow P., Karunarathna U., Khongkow M., Gong C., Gomes A.R., Yague E., Monteiro L.J., Kongsema M., Zona S., Man E.P., Tsang J.W., Coombes R.C., Wu K.J., Khoo U.S., Medema R.H., Freire R., Lam E.W. FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance. Oncogene 2014, 33:4144-4155.